# üéØ BRIACELL THERAPEUTICS - COMPANY PROFILE

**Last Updated:** November 15, 2025  
**Status:** üî• **ACTIVE TARGET** (First real pitch)

---

## üìä COMPANY OVERVIEW

| Field | Details |
|-------|---------|
| **Company Name** | BriaCell Therapeutics Corp. |
| **Ticker** | BCTX (NASDAQ) |
| **Headquarters** | Berkeley, CA, USA |
| **Founded** | 2006 |
| **CEO** | Dr. William V. Williams, MD |
| **Stage** | Clinical-stage immunotherapy company |
| **Focus** | Metastatic breast cancer (MBC) |
| **Key Technology** | Bria-IMT‚Ñ¢ (targeted immunotherapy) + Bria-OTS‚Ñ¢ (off-the-shelf) |

---

## üî¨ PIPELINE & CLINICAL TRIALS

### **Phase 3 Trial: BRIA-ABC (NCT06072612)**

| Field | Details |
|-------|---------|
| **Trial Name** | BRIA-ABC Phase 3 |
| **ClinicalTrials.gov ID** | NCT06072612 |
| **Status** | Recruiting |
| **Indication** | Metastatic Breast Cancer (MBC) |
| **Intervention** | Bria-IMT‚Ñ¢ + Retifanlimab vs TPC (Treatment Physician's Choice) |
| **Patient Population** | HER2+, HER2-, TNBC (heterogeneous) |
| **Primary Endpoint** | Overall Survival (OS) |
| **Secondary Endpoints** | Progression-Free Survival (PFS), Clinical Benefit Rate (CBR), **CNS Event-Free Survival** |
| **Sample Size** | TBD (likely 200-400 patients) |
| **Timeline** | Enrolling 2024-2026, results expected 2027-2028 |

---

## üéØ PAIN POINTS (OUR OPPORTUNITY)

### **1. Patient Heterogeneity**
- **Problem:** Trial enrolls HER2+, HER2-, TNBC patients (very different biology)
- **Risk:** Diluted response signals ‚Üí lower statistical power ‚Üí trial failure
- **Our Solution:** Pre-enrollment genomic stratification ‚Üí enrich for responders

### **2. CNS Metastasis Secondary Endpoint**
- **Problem:** CNS event-free survival is tracked but not prevented
- **Opportunity:** 30-40% of MBC patients develop brain mets (leading cause of death)
- **Our Solution:** Identify high-risk patients + design CRISPR guides targeting CNS metastasis drivers (CXCR4, MMP2, VEGFA)

### **3. Checkpoint Inhibitor Pairing Strategy**
- **Problem:** Bria-IMT‚Ñ¢ primes tumors, but which patients need checkpoint inhibitor (Retifanlimab)?
- **Risk:** Unnecessary toxicity if all patients get combo (some may respond to Bria-IMT‚Ñ¢ alone)
- **Our Solution:** Genomic signatures predicting checkpoint inhibitor sensitivity

### **4. Bria-OTS‚Ñ¢ Pipeline Expansion (1H2025 IND Filings)**
- **Problem:** Need to discover targets for prostate, lung, melanoma (different metastatic biology)
- **Timeline Pressure:** 1H2025 IND filings (6 months away)
- **Our Solution:** 6-week target discovery + CRISPR guide design (vs 18-month traditional discovery)

---

## üí∞ FINANCIAL & STRATEGIC CONTEXT

### **Funding & Burn Rate**
- **Market Cap:** ~$50-100M (NASDAQ:BCTX)
- **Cash Runway:** Estimated 12-18 months (typical for clinical-stage biotech)
- **Pressure:** Need Phase 3 success to secure next financing round

### **Strategic Imperatives**
1. **De-risk Phase 3 trial** (patient stratification = higher success probability)
2. **Expand pipeline** (Bria-OTS‚Ñ¢ for multiple indications)
3. **Build companion diagnostic** (genomic stratification ‚Üí precision oncology positioning)
4. **Attract pharma partnership** (success in Phase 3 ‚Üí acquisition target for Big Pharma)

---

## üéØ OUR VALUE PROPOSITION (TIERED)

### **Tier 1: Patient Stratification Pilot ($250K, 6 weeks)**

**Deliverables:**
- Genomic analysis of 50-100 trial patients (RNA-seq or WES data)
- Per-patient response prediction scores (0-1 scale)
- Metastatic cascade profiling (which steps are active per patient)
- Checkpoint inhibitor sensitivity biomarkers
- 20-page report + presentation

**Expected Impact:**
- **Scenario 1:** If 30% top stratum shows 2√ó response ‚Üí adaptive randomization increases power 20-30%
- **Scenario 2:** If genomic signature reaches AUROC >0.80 ‚Üí companion diagnostic for label expansion
- **Scenario 3:** At minimum ‚Üí publishable biomarker study for CNS-EFS secondary endpoint

**ROI for BriaCell:**
- $250K investment vs potential $100M+ value increase if Phase 3 succeeds
- 50:1 risk-reward ratio

---

### **Tier 2: CRISPR Guide Design for Resistance Prevention ($500K, 12 weeks)**

**Deliverables:**
- Target selection: Analyze Phase 2 non-responders, identify escape mechanisms
- 60 CRISPR guides for 3 resistance targets (e.g., PD-L1 loss, CXCR4 overexpression, MMP2)
- Computational validation: efficacy (mean 0.548), safety (mean 0.771), structural confidence (pLDDT 80.1)
- In vitro validation plan: Assays for BriaCell's cell lines (co-funded 50%)

**Expected Impact:**
- Convert resistant patients to responders (restore checkpoint sensitivity)
- Block CNS metastasis (improve CNS-EFS secondary endpoint)
- Enhance T-cell infiltration (increase TILs)

**ROI for BriaCell:**
- $500K investment ‚Üí novel combination therapy ‚Üí expanded indications ‚Üí $500M+ market opportunity

---

### **Tier 3: CNS Metastasis Prevention Co-Development ($2M, 18 months)**

**Deliverables:**
- **Phase 1:** Biomarker development (6 months, $250K) - identify genomic features predicting CNS mets
- **Phase 2:** CRISPR guide library (12 months, $750K) - 40 guides targeting CNS cascade, validated in mouse models
- **Phase 3:** IND preparation (18 months, $1M) - Bria-CNS‚Ñ¢: Bria-IMT + anti-CXCR4 guide (prevent brain seeding)

**Expected Impact:**
- First-in-class CNS metastasis prevention therapy
- Companion diagnostic for brain met risk
- Expanded indication beyond current Bria-IMT‚Ñ¢ label
- IP co-ownership (2-5% royalty on CNS prevention indication)

**ROI for BriaCell:**
- $2M investment ‚Üí $1B+ market opportunity (CNS prevention is massive unmet need)

---

## üéØ DECISION MAKERS & CONTACTS

### **Primary Contact: Dr. William V. Williams (CEO)**
- **Email:** TBD (search LinkedIn/company website)
- **Background:** MD, extensive oncology experience
- **Decision Authority:** Final say on strategic partnerships
- **Approach:** High-level pitch (business value, de-risking Phase 3, pipeline expansion)

### **Secondary Contacts:**
- **CSO/CMO:** TBD (identify from LinkedIn/company website)
  - **Decision Authority:** Technical validation, trial design
  - **Approach:** Technical deep-dive (AUROC 0.976, S/P/E framework, validation data)

- **Head of R&D:** TBD
  - **Decision Authority:** CRISPR guide design, Bria-OTS‚Ñ¢ pipeline
  - **Approach:** Guide design capabilities, 6-week turnaround, structural validation

---

## üìß OUTREACH STRATEGY

### **Step 1: Cold Email (Tier 1 Pitch)**
- **Status:** ‚úÖ Drafted & corrected (`outreach_email_FIXED.md`)
- **Timing:** Send Week 3 (November 18, 2025)
- **Attachment:** 1-pager PDF (General1Page_CORRECTED.tsx exported)

### **Step 2: Follow-Up Sequence**
- **Day 3:** Soft reminder (if no response)
- **Day 7:** Value-add content (send Metastasis V1 preprint)
- **Day 14:** Breakup email (close the loop)

### **Step 3: Discovery Call (20 min)**
- **Goal:** Understand their pain points, qualify fit
- **Script:** `discovery_call_script.md` (to be created)
- **Outcome:** Go/no-go decision on free pilot

### **Step 4: Free Pilot Proposal**
- **Offer:** Analyze 20 Phase 2 patients (no cost, proof-of-concept)
- **Goal:** Prove genomic scores correlate with actual response
- **Document:** `free_pilot_proposal.md` (to be created)

### **Step 5: Paid Pilot Proposal**
- **Offer:** $250K, 50-100 patients, 6 weeks
- **Goal:** Full Phase 3 patient stratification
- **Document:** `paid_pilot_proposal.md` (to be created)

---

## üéØ COMPETITIVE INTELLIGENCE

### **Who Else is Pitching BriaCell?**
- **Benchling:** CRISPR guide design tools (manual, slow)
- **Recursion Pharma:** Phenomics + AI drug discovery (not genomic stratification)
- **Foundation Medicine:** Genomic testing (limited to FDA-approved panels, <1% of genome)
- **Tempus:** Multi-omic profiling (comprehensive but no stratification algorithms)

### **Our Differentiation:**
- **Whole-genome analysis** (vs <1% of genome)
- **Multi-modal scoring** (S/P/E framework vs single metrics)
- **Validated performance** (AUROC 0.976 vs unproven)
- **6-week turnaround** (vs 18-month traditional discovery)
- **Research-grade transparency** (provenance, audit trails, RUO disclaimers)

---

## ‚úÖ NEXT ACTIONS (IMMEDIATE)

**Commander (This Week):**
- [ ] Export General1Page_CORRECTED.tsx to PDF
- [ ] Finalize cold email (personalize subject line, Dr. Williams name)
- [ ] Send cold email + PDF attachment (November 18, 2025)
- [ ] Add to tracking CSV (date sent, status)

**Commander (Next Week):**
- [ ] Create `discovery_call_script.md` (talking points, objection handling)
- [ ] Create `free_pilot_proposal.md` (20-patient retrospective)
- [ ] Create `paid_pilot_proposal.md` ($250K, 50-100 patients)
- [ ] Monitor inbox for response (check daily)

**Commander (Week 3+):**
- [ ] Follow-up Day 3 (if no response)
- [ ] Follow-up Day 7 (value-add content)
- [ ] Discovery call (20 min, scheduled)
- [ ] Free pilot proposal sent (proof-of-concept)
- [ ] Paid pilot proposal sent (after free pilot proves value)

---

## üìä SUCCESS CRITERIA

**Email Success:**
- Response rate: Target 10-15% (Tier 1 pitch)
- Discovery call scheduled: Yes/No

**Discovery Call Success:**
- Pain points validated: Yes/No
- Interest level: High/Medium/Low
- Next step agreed: Free pilot / Paid pilot / No fit

**Pilot Success:**
- Free pilot: Genomic scores correlate with response (AUROC >0.70)
- Paid pilot: $250K signed, 50-100 patients analyzed
- Long-term: Platform license ($1-5M/year)

---

**‚öîÔ∏è BRIACELL IS OUR FIRST CONQUEST. EXECUTE WITH PRECISION.**
